Support the Institute

The Belfer Legacy

In 1999, with generous support from the Arthur and Rochelle Belfer Foundation, the Belfer Center for Cancer Genomics was founded. The center initially focused on developing high-resolution platforms and computational tools for global genomic profiling of patterns of copy number aberrations in human cancers. The center established a robust pipeline for high-throughput genomic analyses of human and mouse tumors, and became one of The Cancer Genome Atlas’ select Cancer Genome Characterization Centers during its Pilot Phase (2006-2009).

In 2004, the Center for Applied Cancer Science at Dana-Farber Cancer Institute was established, designed to bring together the best attributes of academia and industry to rapidly translate cancer genomics knowledge into more effective cancer therapies. In 2006, with a visionary commitment from the Robert A. and Renee E. Belfer Foundation, the Belfer Center for Cancer Genomics and the Center for Applied Cancer Science became the Belfer Institute for Applied Cancer Science.

In the News

Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".

read more >

Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.

read more >

Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.

read more >

Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer

read more >

Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer

read more >

Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.

read more >

Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.

read more >

Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.

read more >